Keywords
How to Cite
Abstract
Breast cancer is the leading cause of mortality for women in Brazil, however, this pathology also affects 1% of men. It is noteworthy that the hormone therapy used for gender transition is associated with a high incidence of cancers worldwide. The process of adapting a person's sexual characteristics to the desired sex is called transitioning. Thus, transgender is a broad term that refers to people who do not identify with or conform to typical expressions, roles, or behaviors associated with being male or female to which they were assigned at birth (American Psychological Association, 2018). The trans woman was assigned male at birth, but identifies as female, and hormone therapy is a resource used to phenotypically modify the characteristics of the respective genders. In addition, this treatment is made available by the Unified Health System (SUS), for people from 16 years of age, since on January 9, 2020, the Federal Council of Medicine revokes resolution CFM nº 1.955/2010 to CFM nº 2,265/2019, meeting the minimum age for initiation of crossed hormone treatment from 18 to 16 years. Therefore, there is an increase in the age window for treatment follow-up, consequently a greater population contingent exposed to the risk of breast cancer. In order to reveal the importance of neglected issues, this review study points out data relevant to the health and prevention of breast cancer in transgender women.
References
BEDRICK, B. S.; FRUHAUF, T. F.; MARTIN, S. J.; FERRISS, J. S. Creating Breast and /Gynecologic Cancer Guidelines for Transgender Patients With BRCA Mutations. Obstetrics & Gynecology, v. 138, n. 6, p. 911–917, dez. 2021.
BRASIL. Ministério da Saúde. Brasil registrou 207 óbitos de homens por câncer de mama em 2020. 03 nov. 2022a. Disponível em: https://www.gov.br/saude/ptbr/assuntos/noticias/2022/outubro/brasil-registrou-207-obitos-dehomens-por-cancerde-mama-em-2020. Acesso em: 26 de abr. 2023.
BRASIL. Ministério da Saúde. Fatores de risco: Fatores relacionados ao aumento do risco de desenvolver o câncer de mama. 01 out. 2022b. Disponível em: https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-docancer-demama/fatores-de-risco. Acesso em: 26 de abr. 2023.
CARVALHO, M. D.S.; DOS SANTOS, M. T. S.; SILVA, P. T. D.H.; GOMES, J. P.; E SILVA, P. M.; DE ALBUQUERQUE, G. C.; VALGUEIRO, N. D.C.L. Desafios do rastreio do câncer de mama em pessoas transgêneros. Research, Society and Development, v. 10, n. 9, p. e11810917772-e11810917772, 2021.
CUNDILL, P. Hormone therapy for trans and gender diverse patients in the general practice setting. Australian Journal of General Practice, v. 49, n. 7, p. 385–390, 1 jul. 2020.
DA COSTA, T. L. A. C.; BRANDÃO, F. D.S. S.; FIGUEIREDO, W. V. A.; PASSOS, X.S.; MORAIS, F. D. Influência da hormonioterapia na incidência de câncer em transexuais Influence of hormone therapy on cancer incidence in transsexuals. Brazilian Journal of Development, v. 7, n. 6, p. 56017-56039, 2021.
DE BLOK, C. J. M.; WIEPJES, C. M.; NOTA, N. M.; VAN ENGELEN, K.; ADANK, M. A.; DREIJERINK, K. M. A.; BARBÉ, E.; KONINGS, I.R.H.M.; DEN HEIJER, M. Breast câncer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. Bmj, v. 365, 2019.
DE BLOK, C. J. M.; DIJKMAN, B. A. M.; WIEPJES, C. M.; KONINGS, I. R. H. M.; DREIJERINK, K. M. A.; BARBÉ, E.; DEN HEIJER, M. Frequency and outcomes of benign breast biopsies in trans women: A nationwide cohort study. The Breast, v. 57, p. 118–122, jun. 2021.
HAUPT, C.; HENKE, M.; KUTSCHMAR, A.; HAUSER, B., BALDINGER, S.; SAENZ, S. R. SCHREIBER, G. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. Cochrane Database of Systematic Reviews, v. 2020, n. 11, 28 nov. 2020.
LABANCA, T.; MAÑERO, I.; PANNUNZIO, M. Transgender patients: considerations for routine gynecologic care and cancer screening. International Journal of Gynecologic Cancer, v. 30, n. 12, p. 1990–1996, dez. 2020.
LUEHMANN, N.; ASCHA, M.; CHWA, E.; HACKENBERGER, P.; TERMANINI, K.; BENNING, C.; SAMA, D.; FELT, D.; BEACH, L. B.; GUPTA, D.; KULKARNI, S. A.; JORDAN, S.W. A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients. Annals of Surgical Oncology, v. 29, n. 3, p. 1707–1717, mar. 2022.
MCFARLANE, T.; ZAJAC, J. D.; CHEUNG, A. S. Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review. Clinical endocrinology, v. 89, n. 6, p. 700-711, 2018.
O’BRYAN, J.; WOLF-GOULD, C.; MATSUO, Y. Mammary Myofibroblastoma in a Transgender Patient on Feminizing Hormones: Literature Review and Case Report. Transgender Health, v. 3, n. 1, p. 1–9, maio 2018.
PARIKH, U.; MAUSNER, E.; CHHOR, C. M.; GAO, Y.; KARRINGTON,I.; HELLER, S. L. Breast Imaging in Transgender Patients: What the Radiologist Should Know. RadioGraphics, v. 40, n. 1, p. 13–27, jan. 2020.
PETERS, M. D. J.; RAMSEY, I.; KENNEDY, K.; SHARPLIN, G.; ECKERT, M. Culturally safe, highquality breast cancer screening for transgender people: A scoping review protocol. Journal of Advanced Nursing, v. 78, n. 1, p. 276–281, jan. 2022.
SCHMIDT, M.; DITRIO, L.; SHUTE, B.; LUCIANO, D. Surgical management and gynecologic care of the transgender patient. Current Opinion in Obstetrics and Gynecology, v. 31, n. 4, p. 228-234, 2019.
SUTHERLAND, N.; ESPINEL, W.; GROTZKE, M.; COLONNA,S. Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. Journal of Genetic Counseling, v. 29, n. 4, p. 625–633, ago. 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Daniely Silva, Ana Júlia de Mello Toledo, José ´´Everton Delmondes Bento, Giulia Bernini, William Davila Delgallo